Detection, Control, and Management of a Respiratory Syncytial Virus Outbreak in a Pediatric Hematology-Oncology Department


Shachor-Meyouhas Y., Zaidman I., Kra-Oz Z., Arad-Cohen N., Kassis I.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, vol.35, no.2, pp.124-128, 2013 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.1097/mph.0b013e3182756edc
  • Journal Name: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.124-128

Abstract

Background: Immunocompromised patients are at increased risk for severe respiratory syncytial virus (RSV) infection. Palivizumab is approved for prevention of RSV in specific populations but not for treatment. Few studies demonstrated the safety and successful treatment with intravenous (IV) palivizumab. We describe our experience with IV palivizumab treatment for RSV in a pediatric hematology-oncology department during an outbreak.